Search results for "nimet"

showing 10 items of 108 documents

Napoleon in Central Finland: The Fashion of Giving Children Rulers’ Names

2012

EstelleNapoleonetunimetforenamesnimimuoditnaming fashionshallitsijanimetnimistöhistoriarulers' namesonomastic history
researchProduct

Tavoitteena vahva ja yhtenäinen kansa : historia ja kieli kansallisen identiteetin rakentamisen välineinä Pätsin aikakauden Virossa 1934-1940

2018

In this dissertation, I study national campaigns aimed at constructing Estonian national identity in 1934–1940. The campaigns were organized through the cooperation of Konstantin Päts’ authoritarian government and civil society. I focus on the folk art campaign and on the name changing campaign. The name changing campaign was the largest national project in Estonia, aiming at the Estonification of names. Initially, the campaign focused on changing individuals’ surnames and first names, but later also on changing the names of places, streets and properties. The name changing campaign had history political and language political dimensions. Through the folk art campaign, the state tried to af…

EstonianimenmuutoksethistoriapolitiikkaLaidoner Johankansanperinnesymbolitestonification of namesnational identitykansankulttuuriidentiteettiPäts Konstantinkansantaidepolitics of historyvirolaistamiskampanjatpolitics of identityhistorialliskvalitatiivinen menetelmähenkilönnimetpropagandaViron sivistysliittopolitics of language1930-lukuyhtenäisyyskielipolitiikkakansallinen identiteettisanomalehdetnational campaignsfolk art campaignvirolaisuusEenpalu Kaarellaadullinen sisällönanalyysi
researchProduct

Finnish fandom of Japanese popular culture : what are the Finns doing for anime, manga, and J-rock?

2010

InternetverkkoyhteisötJapaniverkostoituminenmangatrockfaniuskulttuurianimetdigitaalinen kulttuuriSuominuorisokulttuuripopulaarikulttuuriJ-rock
researchProduct

Somalialaistaustaiset nuoret nimistönkäyttäjinä Itä-Helsingissä

2011

Artikkelin tutkimuskohteena ovat Itä-Helsingissä asuvat somalialaistaustaiset nuoret. Tutkimuksessa tarkastellaan somalialaistaustaisten nuorten omassa asuinympäristössään käyttämää paikannimistöä sekä nimistöhaastattelujen tavoitteita ja tuloksia. Tutkimuksen aineistona on viiden iältään 12–17-vuotiaan somalialaistaustaisen haastattelut, jotka on tehty vuonna 2008. Haastattelut ovat olleet ryhmähaastatteluja, joissa nuoret keskustelevat omasta asuinympäristöstään. Tukiaineistona on käytetty sekä aikuisten somalialaistaustaisten että suomalaistaustaisten itähelsinkiläisten haastatteluja. Tutkimus liittyy kahteen Suomen Akatemian hankkeeseen: Nimimaiseman muutos Helsingin sosiolingvistisesti…

Itä-Helsinkinimistöntutkimushaastattelumetodikansanonomastiikkasomalialaistaustaiset nimet
researchProduct

Mikä kunnalle nimeksi? : etnologinen tutkimus kunnan nimen merkityksestä kuntalaisille Kouvolan kuntaliitoksen toteuttamisen aikana

2016

Tarkastelen pro gradu -tutkielmassani kunnan nimen merkitystä kunnan asukkaille. Tarkoituksenani on syventää ymmärrystä siitä, miksi kunnan nimi aiheuttaa paljon keskustelua kuntaliitoksen toteuttamisen aikana. Tutkielmaani varten keräsin Kouvolan seudun uuden kunnan nimeä käsitteleviä tekstiviestikommentteja Kouvolan Sanomien Napakat-mielipidepalstalta. Viestien analysoinnissa käytin lähilukua sekä tulkitsevaa diskurssianalyysia. Teoreettisena viitekehyksenä tutkielmassani toimivat kuntasamaistumisen ja psykologisen omistajuuden käsitteet. Aineistosta käy ilmi, että kunnan asukkaille merkityksellisessä kunnan nimessä yhdistyvät kuntalaisten kokemukset kunnasta sekä nimen paikannettavuus ni…

Kouvolatulkitseva diskurssianalyysisamaistuminenmerkityksetDiskurssianalyysikuntaliitoksetkunnatnimetasukkaatpsykologinen omistajuuskunnan nimikuntaliitoslähilukukuntasamaistuminen
researchProduct

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multice…

2018

Summary Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF V600 -mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. Methods COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or metastatic cutaneous melanoma, or unknown primary melanoma, BRAF V600E or BRAF V600K mutation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were treatment naive or had pr…

Male0301 basic medicineOncologySkin NeoplasmsTime FactorsMedizinPhases of clinical researchGene mutationchemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsVemurafenibMelanomaAged 80 and overTrametinibSulfonamides10177 Dermatology ClinicBinimetinibMiddle AgedProgression-Free SurvivalPhenotypeOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFemale2730 Oncologymedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialty610 Medicine & healthYoung Adult03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansGenetic Predisposition to DiseaseProgression-free survivalProtein Kinase InhibitorsAgedPerformance statusbusiness.industry030104 developmental biologyVemurafenibchemistryMutationBenzimidazolesCarbamatesbusinessThe Lancet Oncology
researchProduct

Validity of five foot and ankle specific electronic patient-reported outcome (ePRO) instruments in patients undergoing elective orthopedic foot or an…

2019

Background: Patient-reported outcomes (PROS) are widely accepted measures for evaluating outcomes of surgical interventions. As patient-reported information is stored in electronic health records, it is essential that there are valid electronic PRO (ePRO) instruments available for clinicians and researchers. The aim of this study was to evaluate the validity of electronic versions of five widely used foot and ankle specific PRO instruments. Methods: Altogether 111 consecutive elective foot/ankle surgery patients were invited face-to-face to participate in this study. Patients completed electronic versions of the Foot and Ankle Ability Measure (FAAM), the Foot and Ankle Outcome Score (FAOS),…

MalepsychometricsVisual Analog Scaleclinimetricsleikkaushoito0302 clinical medicineSurveys and QuestionnairesElectronic Health RecordsOrthopedics and Sports MedicinePatient-reported outcomevalidation030222 orthopedicsMiddle AgedElectronic patient-reported outcomePRO MEASURES3. Good healthpsykometriikkamedicine.anatomical_structureConvergent validityvalidointiFemalePatient-reported outcomeEQUIVALENCEFoot (unit)medicine.medical_specialtyPsychometricsVisual analogue scaleQUESTIONNAIREpatient-reported outcomeVALIDATIONANALOG SCALE FOOTePRO03 medical and health sciencesClinimetricsanklemedicineQUALITYCOSMINHumansPatient Reported Outcome MeasuresFootbusiness.industryReproducibility of ResultsConstruct validity030229 sport sciences3126 Surgery anesthesiology intensive care radiologyjalatSurgerySYSTEMATIC REVIEWSnilkathoitotuloksetfootOrthopedic surgeryPAPERAnkleAnklebusinessAnkle JointTASK-FORCEFoot and Ankle Surgery
researchProduct

Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, m…

2021

9555 Background: For the treatment of advanced BRAFV600-mutated melanoma, targeted therapy (BRAF/MEK-inhibition) is a standard of care. Encorafenib + binimetinib (EB) were approved in the EU in Sep 2018 and in Switzerland in Nov 2019, based on positive results from COLUMBUS (NCT01909453), with a median progression-free survival (PFS) of 14.9 mo (4-year PFS: 26%) and overall survival (OS) of 33.6 mo (4-year OS: 39%). As data from controlled trials are based on selected populations, BERINGMELANOMA investigates the use of EB under real-world conditions in a broader population. Methods: BERINGMELANOMA is an ongoing, multi-national, multi-center, prospective, longitudinal, non-interventional st…

OncologyCancer Researchmedicine.medical_specialtyLongitudinal studyStandard of carebusiness.industrymedicine.medical_treatmentMelanomaMedizinLocally advancedBinimetinibmedicine.diseaseTargeted therapychemistry.chemical_compoundOncologychemistryInternal medicineNon interventionalMedicineIn patientbusinessJournal of Clinical Oncology
researchProduct

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients…

2021

9507 Background: Combined BRAF/MEK inhibitor therapy has demonstrated benefits on progression-free survival (PFS) and OS and is standard of care for the treatment of advanced BRAF V600-mutant melanoma. Here we report a 5-year update from the COLUMBUS trial. Methods: In Part 1 of COLUMBUS, 577 pts with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomized 1:1:1 to encorafenib 450 mg QD + binimetinib 45 mg BID (COMBO450), encorafenib 300 mg QD (ENCO300), or vemurafenib 960 mg BID (VEM). An updated analysis including PFS, OS, objective response rate (ORR; by blinded independent central review), and safety was conducted after min…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryMelanomaMEK inhibitorMutantBinimetinibmedicine.diseasechemistry.chemical_compoundOncologychemistryInternal medicineEncorafenibmedicineOverall survivalIn patientVemurafenibbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-muta…

2017

Oncologymedicine.medical_specialtybusiness.industryMelanomaMutantBinimetinibHematologymedicine.disease030226 pharmacology & pharmacyDermatology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOncologychemistryInternal medicineEncorafenibmedicinebusinessVemurafenib030217 neurology & neurosurgerymedicine.drugAnnals of Oncology
researchProduct